Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GPRC5D monoclonal antibody SAR446523

A Fc-engineered immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GPRC5D monoclonal antibody SAR446523 targets and binds to GPRC5D expressed on certain tumor cells. This results in an antibody-dependent cell-mediated cytotoxicity (ADCC) against GPRC5D-expressing tumor cells, thereby killing the cancer cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:SAR 446523
SAR-446523
SAR446523
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search